List of Dexmedetomidine Hydrochloride drug patents

Dexmedetomidine Hydrochloride is owned by Hq Spclt Pharma.

Dexmedetomidine Hydrochloride contains Dexmedetomidine Hydrochloride.

Dexmedetomidine Hydrochloride has a total of 2 drug patents out of which 0 drug patents have expired.

Dexmedetomidine Hydrochloride was authorised for market use on 21 October, 2015.

Dexmedetomidine Hydrochloride is available in solution;intravenous dosage forms.

The generics of Dexmedetomidine Hydrochloride are possible to be released after 20 April, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(13 years from now)

US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(13 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in